Adeno-associated Virus Serotype 8 (AAV8) Delivery of Recombinant A20 to Skeletal Muscle Reduces Pathological Activation of Nuclear Factor (NF)-κB in Muscle of mdx Mice
- 27 Downloads
Duchenne muscular dystrophy (DMD) is a genetic muscle disease caused by the absence of a functional dystrophin protein. Lack of dystrophin protein disrupts the dystrophin-glycoprotein complex causing muscle membrane instability and degeneration. One of the secondary manifestations resulting from lack of functional dystrophin in muscle tissue is an increased level of cytokines that recruit inflammatory cells, leading to chronic upregulation of the nuclear factor (NF)-κB. Negative regulators of the classical NF-κB pathway improve muscle health in the mdx mouse model for DMD. We have previously shown in vitro that a negative regulator of the NF-κB pathway, A20, plays a role in muscle regeneration. Here, we show that overexpression of A20 by using a muscle-specific promoter delivered with an adeno-associated virus serotype 8 (AAV8) vector to the mdx mouse decreases activation of the NF-κB pathway in skeletal muscle. Recombinant A20 expression resulted in a reduction in number of fibers with centrally placed nuclei and a reduction in the number of T cells infiltrating muscle transduced with the AAV8-A20 vector. Taken together, we conclude that overexpression of A20 in mdx skeletal muscle provides improved muscle health by reduction of chronic inflammation and muscle degeneration. These results suggest A20 is a potential therapeutic target to ameliorate symptoms of DMD.
Duchenne muscular dystrophy (DMD) is one of the most common muscle disorders, affecting about 1 in 3,500–6,000 males worldwide (1). It is caused by mutations in the dystrophin gene, resulting in the absence of or a dysfunctional dystrophin protein (2), and thus disruption of the dystrophin-glycoprotein complex (DGC) required for muscle membrane stability (3). Loss of the DGC causes increased tissue levels of several cytokines, such as tumor necrosis factor (TNF)-α, which recruits inflammation to the tissue (4,5) and activates the nuclear factor (NF)-κB signaling pathway (6,7). Chronic activation of the NF-κB pathway in muscle contributes to the onset and progression of DMD pathology in muscle by activating several downstream targets that affect muscle health (8, 9, 10). The NF-κB pathway plays a role in inducing the ubiquitin-proteasome pathway in muscle (11), causing increased protein degradation (12,13). Myogenic differentiation (MyoD) and myogenic factor-5 (Myf-5) are myogenic regulatory factors that play a role in normal murine muscle development and differentiation (14). MyoD expression was shown to be downregulated by the activation of the NF-κB pathway (15). Also, chronic activation of the NF-κB pathway in turn induces increased cellular infiltration of muscle, thus amplifying inflammation. Agents that prevent pathological activation of the NF-κB pathway have been shown to improve muscle health and decrease inflammation in muscle (16, 17, 18).
Several previous studies in mdx mice focused on inhibition of pathological NF-κB activation as a therapeutic target to ameliorate DMD symptoms. Inhibition of NF-κB activation in mdx mice promoted restoration of muscle membrane stability and regeneration capacity and led to a reduction in inflammation in muscle tissue (16,19). TNF-α-induced protein 3 (TNFAIP3), also known as A20, is a deubiquitinating enzyme that regulates NF-κB activation. A20 contains an N-terminal ovarian tumor (OTU) domain and seven C-terminal zinc-finger domains (20). TNF-α binds to its receptor and recruits the intracellular adaptor protein receptor-interacting protein 1 (RIP1). A20 subsequently deubiquitinates RIP1 at lysine 63 and then reubiquitinates RIP1 at Lysine 48, marking it for degradation, thus inhibiting activation of the NF-κB signaling pathway (21). We have previously demonstrated that A20 plays a critical role in NF-κB pathway inhibition in skeletal muscle (22). Therefore, A20 has the potential to act as an intrinsic potent negative regulator of the NF-κB pathway, unlike many other therapeutic drugs currently being studied for amelioration of the pathway. Taken together, we hypothesized that delivery of recombinant A20 would offer therapeutic benefit for the treatment of dystrophic muscle in muscular dystrophy patients.
Recombinant adeno-associated virus (AAV) vectors are promising gene therapy delivery vehicles for a wide range of human diseases. There are different serotypes of AAV, and these show distinct tissue tropism and transduction efficiencies. AAV serotype 8 (AAV8) achieves a high efficiency of transduction of skeletal muscle and heart (23,24). AAV8 efficiently transduces both fast and slow skeletal muscle fibers with equal efficiency (25). Therefore, to explore the potential of A20 as a therapeutic target to ameliorate DMD symptoms in mdx mice, we used AAV8 to overexpress A20 in skeletal muscle. To restrict expression of A20 to skeletal muscle, we used the truncated muscle creatine kinase (tMCK) promoter (26). The tMCK promoter, which is about 720 base pair (bp) in length, was generated by ligating a triple tandem repeat of the MCK enhancer to its basal promoter, thus generating a strong, muscle-specific promoter (26) sufficiently small to be carried with the A20 cDNA by the AAV vector. Within muscle tissue, the tMCK promoter has preferential expression in fast-twitch fibers. The promoter, however, was shown to have weak expression in heart, diaphragm and liver (26). Here, we analyze the effects of A20 overexpression in skeletal muscle driven by a tMCK promoter by using an AAV8 vector.
Materials and Methods
Mice and Reagents
C57BL/10ScSn-Dmdmdx/J (mdx) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and were housed at the University of Pittsburgh Animal Housing Facility and used under approval by the University of Pittsburgh Institutional Animal Care and Use Committee.
Antibodies used for Western blotting and immunohistochemical analyses were A20 (sc-22834), RelB (sc-28689), GAPDH (sc-25778), MyoD (sc-760) and Myf-5 (sc-302). The secondary antibody for Western blotting was goat anti-rabbit horseradish peroxidase (HRP) (sc-2030) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibodies for immune cells included those for CD4 T cells (16-0041-81) (eBiosciences, San Diego, CA, USA), CD8 T cells and secondary antibody, biotinylated goat anti-rat IgG (Pharmingen, San Jose, CA, USA). Monoclonal antibodies were used to detect myosin heavy chain (MHC, Fast and Slow) (Vector Laboratories, Burlingame, CA, USA). The monoclonal antibody to embryonic MHC (eMyHC) (F1.652), used to detect regenerating fibers, was obtained from the Developmental Studies Hybridoma Bank, developed by Helen Blau (University of Iowa, Department of Biological Sciences, Iowa City, IA, USA).
Virus Preparation and Injections
The recombinant AAV8-tMCK-A20 vector used in this study was constructed by using an A20 plasmid that was obtained from the BCCM/LMBP plasmid collection (LMBP 4801; Department of Biomedical Molecular Biology, Ghent University, Zwijnaarde, Belgium). The tMCK promoter DNA (26) and AAV-tMCK-GFP plasmid, used as a control, were obtained from Bing Wang (University of Pittsburgh, PA, USA). The tMCK-GFP expression cassette was carried by a double-stranded AAV (dsAAV) vector; however, the tMCK-A20 expression cassette was carried by a single-stranded AAV (ssAAV) vector because of its large size. For large-scale production of the virus, the three-plasmid cotransfection method was applied in AAV-293 cells, as described previously (42,43).
Neonatal mdx pups (2–3 d old; males and females) were given an intraperitoneal injection of 6.25 × 1010 vector genomes (vg) in a volume of about 30 µL. The numbers of mice injected are stated in Results. As a control, age-matched pups were given an intraperitoneal injection of 30 µL of either saline or AAV8-ISceI.AO7 vector, which is a modified version of AAV8-ISceI.AO3 (accession number-EU022316) (44). This vector does not express transgene products in mammalian cells.
Electrophoretic Mobility Shift Assay
Nuclear extracts were obtained from quadriceps and diaphragm muscle samples of vector- or saline-injected mdx mice by using NE-PER Nuclear and Cytoplasmic Extraction Reagent (ThermoFisher Scientific, Rockford, IL, USA). Protein concentrations of the extracts were measured by the BCA assay (ThermoFisher Scientific). To study NF-κB activity, the nuclear extracts were preincubated with 5x gel shift binding buffer (Promega, Madison, WI, USA) and nuclease-free distilled water. This step was followed by incubation with an a-32P-deooxycytidine triphosphate (CTP)-labeled, double-stranded DNA probe containing the NF-κB binding domain (PerkinElmer, Waltham, MA, USA). The probe was added at a count per minute (cpm) of ∼100,000/µL, to bring the final volume to 10 µL. The NF-µB probe was designed as described previously (45). Briefly, 15-bp annealing nucleotides were annealed to a 31-bp oligonucleotide template at the 3′ end of the template strand. The overhang was filled in with deoxyribonucleotide triphosphates (dNTPs) in conjunction with 32P-dCTP by using Polymerase I, Large (Klenow) Fragment (Invitrogen; Life Technologies, Carlsbad, CA, USA). Labeled reactions were purified by using MicroSpin G50 columns (GE Healthcare, Piscataway, NJ, USA). Oligonucleotide sequences were as follows: NF-µB template: 5′-CAGGG CTGGG GATTC CCCAT CTCCA CAGTT TCACT TC-3′; NF-κB annealing: 5′-GAAGT GAAAC TGTGG-3′ (Integrated DNA Technologies, Coralville, IA, USA). DNA protein complexes were separated on 6% polyacrylamide gels and resolved by electrophoresis in 1× Tris/borate/EDTA (TBE) buffer at 100 V for 1 h. The gel was then dried at 80°C for 1 h and autoradiographed at −80°C for 24–48 h.
Western Blot Analysis
Total lysates from quadriceps muscle and diaphragm tissues were obtained by using a T-PER Tissue Extraction Reagent (ThermoFisher Scientific). Lysates were run on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel for 1 h and transferred onto a Hybond nitrocellulose membrane at 100 V for 90 min. Membranes were blocked by using blocking buffer (1× phosphate-buffered saline [PBS] with 10% goat serum) for 1 h, followed by incubation with specific primary antibodies and HRP-conjugated secondary antibodies. The blot was then incubated with electrochemilumines-cence reagents (GE Healthcare) and autoradiographed to visualize protein bands. Standard protein markers were run with proteins to determine protein size. All quantifications were performed by using MCID software (InterFocus Imaging, Cambridge, UK).
Muscle Tissue Processing
Hind limb muscles and diaphragms obtained from mdx mice were snapfrozen by using 2-methylbutane pre-cooled on dry ice and stored at −80°C. For immunohistochemical analysis, tissue samples were sectioned at a thickness of 10 µm and transferred onto slides.
Quadriceps and diaphragm sections were thawed at room temperature for 5 min and hydrated by using 1× PBS. The sections were then blocked by using blocking buffer (10% goat serum in 1× PBS) for 1 h and probed with specific primary and secondary antibodies diluted in DAKO antibody diluent (Invitrogen; Life Technologies). Sections were then washed and mounted by using Dapi-Fluoromount-G mounting medium in the dark. Sections that were incubated with anti-mouse antibodies were treated with an additional blocking step by using MOM Mouse IgG blocking reagent (Vector Laboratories) in 1x PBS for 1 h. The ratio of fibers with centrally placed nuclei in each group was quantified by counting fibers with centrally placed nuclei and the total number of fibers per field in a section of vector-injected quadriceps compared with saline-injected quadriceps, six to eight fields (∼100-125 fibers per field) per section and two to three sections per mouse. The quantification of centrally nucleated, regenerating and necrotic fibers was carried out in a double-blinded manner by two independent researchers.
For CD4 and CD8 staining, we used a 3,3′-diaminobenzidine (DAB) staining protocol as described previously (46). Briefly, rehydrated sections were blocked in peroxidase blocking reagent (Invitrogen; Life Technologies) for 5 min and then incubated in blocking buffer (10% goat serum in PBS) for 1 h. The sections were then incubated with specific primary antibodies diluted in blocking buffer for 1.5 h. Sections were incubated for 1 h with secondary antibody diluted in DAKO antibody diluent. Sections were incubated with ABC Vectastain avidin-HRP detection solution (Vector Laboratories) for 30 min at room temperature and DAB peroxidase substrate solution (Vector Laboratories) for 4 min. Sections were counter-stained with eosin to visualize muscle fibers. The number of infiltrating cells in each group was quantified by counting the total number of cells per field in a section of vector-injected quadriceps: eight fields (10× magnification) per section and two sections per mouse.
All values are presented as means ± standard error of mean (SEM) from independent animals in each group. Significance was determined by using the two-tailed and unpaired Student t test. p < 0.05 was considered significant.
All supplementary materials are available online at www.molmed.org.
A20 Overexpression Driven by a Muscle-Specific Promoter Accomplished by AAV8 Vector-Mediated Gene Transfer
To confirm that AAV8 vector alone had no effect on dystrophic symptoms, a group of mice received AAV8-ISceI.AO7, an AAV8 vector that does not express the transgene product in mammalian cells, in the same manner. Comparison of NF-κB activation levels in quadriceps muscles of saline-treated and AAV8-ISceI.A07-treated mice, as determined by electrophoretic mobility shift assay (EMSA), revealed no significant difference in NF-κB activation (Supplementary Figure S1). Thus, we studied saline-treated mice as a control for further analysis. Also, as a control, to determine expression levels, age-matched neonatal mdx mice were treated with an intraperitoneal injection of ds-AAV8-tMCK-GFP, and quadriceps muscles from these mice were analyzed for GFP expression. The dsAAV vector and the tMCK promoter were able to drive robust GFP expression in the heart and skeletal muscles, but not in the liver (Supplementary Figure S2) (26). We also compared levels of GFP expressed in various tissues by using the ubiquitous CMV promoter and observed lower GFP expression in skeletal muscles (tibialis anterior [TA] 0.39 ± 0.1, gastrocnemius 0.61 ± 0.2, quadriceps 0.57 ± 0.2; GFP protein levels normalized to GAPDH) compared with GFP driven by the tMCK promoter (TA 0.73 ± 0.3, gastrocnemius 0.77 ± 0.1, quadriceps 0.68 ± 0.1; GFP protein levels normalized to GAPDH; Supplementary Figure S2). These results were similar to those of an earlier study comparing various promoter-driven expression levels in differentiating C2C12 myoblasts (26).
Protein Levels of the RelB Subunit of NF-κB Alternate Signaling Pathway, and Myf-5 Muscle Differentiation Factor Increased on A20 Treatment
A20 Overexpression Decreased Activation of the Classical NF-κB Pathway
Overexpression of A20 Causes a Decrease in the Number of Fibers with Centrally Placed Nuclei in mdx Quadriceps Muscle
A20 Overexpression Decreases Regeneration, but Has No Effect on Necrosis in mdx Quadriceps Muscle
Decrease in Infiltrating Inflammatory T Cells in Quadriceps Muscle of mdx Mice Treated with AAV8-tMCK-A20
Chronic activation of the classical NF-κB signaling pathway in DMD muscle leads to many of the pathological symptoms in DMD (6,30), and it has been shown that inhibition of NF-κB activation ameliorates dystrophic muscle pathology (17,19). We show, for the first time, the role of A20 overexpression as a potential therapeutic target for DMD in mdx mice. We assessed the effect on skeletal muscle pathology in mdx mice of muscle-specific overexpression of A20. We found that increased protein expression of A20 led to a significant decrease in NF-κB pathway activation in quadriceps of mdx mice. We also observed an increase in protein levels of RelB, a subunit of the alternate pathway of NF-κB activation, and Myf-5, a muscle transcription factor required for differentiation. Moreover, we observed a decrease in the number of fibers with centrally placed nuclei and a decrease in markers of regeneration in the quadriceps of mdx mice. Lastly, we detected a reduction in the number of infiltrating inflammatory CD4 T cells in the AAV8-tMCK-A20-treated quadriceps. Taken together, we can conclude that A20 overexpression can reduce the activation of NF-κB and is thus an attractive candidate to further explore as a therapeutic target for the treatment of DMD.
Expression of A20 after systemic delivery with an AAV8 vector carrying the murine A20 cDNA driven by the muscle-specific tMCK promoter was increased 1.4-fold in quadriceps. One possible reason for this modest increase in A20 protein levels may have been due to delivery of an insufficient number of viral genomes. Also, levels of A20 may be affected by its expression by a single-stranded AAV (ssAAV) and not double-stranded AAV (dsAAV) vector. Our studies confirmed prior findings that the dsAAV vector and the tMCK promoter were able to drive robust GFP expression in the heart and skeletal muscles, but not in the liver (26). We confirmed, however, that the tMCK promoter provided transgene expression levels in skeletal muscle that was superior to the ubiquitous CMV promoter. Thus, even with the modest 1.4-fold increase of A20 expression, we provide proof-of-concept by the observation of a significant reduction in the activation of the NF-κB pathway in skeletal muscle. This result supports the hypothesis that overexpression of A20 would regulate the NF-κB pathway in muscle.
Interestingly, we also observed an increase in the expression levels of RelB, which reflects the NF-κB alternate pathway. We previously showed that RelB is overexpressed in regenerating fibers of dystrophic muscle and that A20 plays a role in muscle regeneration by inhibiting the classical but not the alternate pathway of NF-κB activation. Also, the alternate pathway of NF-κB activation was shown by others to be required for myogenesis and maintenance of mature myofibers (31). Thus, we can speculate that overexpression of A20 inhibits the classical pathway of NF-κB activation, which leads to the upregulation of the alternate pathway, promoting muscle regeneration. We also observed an increase in Myf-5, but not MyoD, levels in quadriceps of AAV8-A20-treated mice. Myf-5 and MyoD play essential but redundant roles in muscle development (14), which might explain our findings of increased expression of Myf-5 but not MyoD. However, the dose-dependent effect of AAV8-A20 on the levels of these transcription factors remains to be evaluated.
Absence of dystrophin in skeletal muscle leads to loss of integrity of the muscle membrane, causing muscle fibers to undergo cycles of degeneration and regeneration (32,33). Because of this constant damage to muscle, myofibers become unstable, ultimately leading to protein degradation and muscle atrophy (32). We analyzed the effect of overexpression of recombinant A20 in quadriceps of AAV8-tMCK-A20-treated mdx mice on this cycle of damage and repair and observed a significant decrease in the number of fibers with centrally placed nuclei, a well-studied marker of continuous degeneration and regeneration. Earlier studies have also shown that reduced activation of the classical NF-κB pathway causes decreased regeneration and increased stability of muscle (17,34). Consistent with these studies, we also observed a decrease in the number of regenerating fibers in quadriceps of AAV8-A20-treated mdx mice. This result suggests a decrease in the damaging cycles of myofiber degeneration and regeneration and an overall improvement in muscle health and stability in the skeletal muscles.
The muscle pathology in DMD is thought to be caused by an imbalance between the amount of regeneration and the amount of necrosis in muscle tissue (32). One of the reasons muscle fibers degenerate is because of NF-κB-induced activation of transcription targets such as MuRF1 and atrogin-1 that mediate up-regulation of the ubiquitin-proteasome pathway causing degradation of muscle fibers (28,35,36). We analyzed the effect of A20 overexpression on the number of necrotic fibers in skeletal muscle of treated mdx mice. Surprisingly, overexpression of A20 did not have any effect on necrosis in quadriceps muscle collected at 8 wks of age. We observed no change in the number of necrotic fibers in AAV8-tMCK-A20-treated compared with saline-treated mdx mice. Thus, although we observe a reduction in the markers for regeneration in quadriceps muscles, there is no change in degeneration in the muscles of the treated mice. One explanation for this could relate to the relatively low dose of the A20 transgene delivered to each mouse. Because the A20 transgene was delivered to neonates, its early expression during development could help to maintain the health and stability of muscle fibers by inhibiting activation of the NF-κB pathway. However, the relatively low A20 transgene expression may not have been sufficient to sustain its function to completely inhibit NF-κB activation leading to the transcription of its downstream targets, thus causing necrosis of muscle fibers. Future studies to determine a dose effect of the delivered transgene and the effect of mouse age at the time of gene transfer could aid in the further understanding of the dynamic relationship between necrosis and regeneration in diseased skeletal muscle.
Chronic activation of the NF-κB pathway in skeletal muscle leads to increased concentrations of cytokines and chemokines and the infiltration of inflammatory cells such as macrophages (37). Specifically, CD4 and CD8 T cells were shown to play a role in dystrophic pathology, and depletion of these cells led to improvement of histopathology in mdx mice (38). Because A20 causes reduction of the classical NF-κB pathway activation, we speculated that this reduction would decrease the amount of inflammation in muscle. We observed a reduction in the number of infiltrating CD4 T cells in the quadriceps of AAV8-tMCK-A20-treated mdx mice. We did not, however, observe any decrease in the number of CD8 T cells in these mice. Although, both CD4 and CD8 T cells are known to play a role in inflammation in mdx mice, CD4 T cells are more prevalent in mdx muscle (38). Furthermore, muscle biopsies from DMD patients showed a predominance of CD4 T cells compared with CD8 T cells (32,39). Also, CD4 T cells were found to colocalize with macrophages and degenerating muscle fibers, whereas CD8 T cells were scattered throughout muscle tissue (39). Hence, it was speculated that CD4 T cells, and not CD8 T cells, played a major role in causing cytotoxic muscle damage (39,40). A recent study showed that AAV vectors alone were capable of activating the alternate NF-κB pathway in HeLa cells (41). This was an interesting observation from a therapeutic point of view, since AAV-mediated transfer would be able to not only inhibit the classical pathway, reducing inflammation, but also promote activation of the alternate pathway, promoting improved muscle health.
Here we show that A20 is a potent negative regulator of the classical NF-κB pathway and plays a role in muscle regeneration by inhibition of this pathway in mdx mouse muscle. A20-mediated inhibition of the NF-κB pathway led to decreased dystrophic pathology and improved muscle health. Thus, AAV-mediated delivery of A20 should be explored further as a promising therapeutic target for DMD, and future studies need to be carried out to elucidate the exact mechanism and function of A20 in skeletal muscle.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
The authors thank Daniel Reay and Aditee Shinde for technical assistance and advice. We also thank Bing Wang, PhD, for provision of the AAV-tMCK-GFP plasmid. This work was supported by a VA Merit Review grant and University of Pittsburgh departmental funds and in part was supported by grant DK078388 to H.N.
The authors take full responsibility for the contents of this paper, which do not represent the views of the Department of Veterans Affairs or the U.S. Government.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)